Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecentriq + Cotellic + Zelboraf
atezolizumab + cobimetinib + vemurafenib · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Unresectable or metastatic melanoma with a BRAF V600 mutation, in combination with cobimetinib and vemurafenib.
LAMPGEN ANALYSIS
Why it matters
Combined checkpoint inhibition with BRAF and MEK inhibition in a defined melanoma population.
What research teams should watch
Set up the targeted-treatment lead-in, then coordinate three agents and their toxicity monitoring.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
BRAF-selected unresectable or metastatic melanomaPRIMARY RECORDS